共 40 条
- [21] Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responsesIMMUNITY, 2022, 55 (03) : 512 - +Banta, Karl L.Xu, XiaozhengChitre, Avantika S.Au-Yeung, AmeliaTakahashi, ChikaraO'Gorman, William E.Wu, Thomas D.Mittman, StephanieCubas, RafaelComps-Agrar, LaetitiaFulzele, AmitBennett, Eric J.Grogan, Jane L.Hui, EnfuChiang, Eugene Y.Mellman, Ira
- [23] Assessment of PD-1/PD-L1 colocalization in hepatocellular carcinoma (HCC) using bright-field double labeling and quantitative digital image analysisANNALS OF ONCOLOGY, 2018, 29Mrowiec, T.Wilm, F.Frick-Krieger, E.Silva, M.Terracciano, L.Dussault, I.Ihling, C.
- [24] TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancerCANCER LETTERS, 2021, 499 : 137 - 147Han, Hye SookJeong, SeongjuKim, HyunglaeKim, Hyung-DonKim, A. ReumKwon, MinsukPark, Su-HyungWoo, Chang GokKim, Hee KyungLee, Ki HyeongSeo, Sung PilKang, Ho WonKim, Won TaeKim, Wun-JaeYun, Seok JoongShin, Eui-Cheol
- [25] IL-2 synergizes with PD-1/PD-L1 blockade via CD28/CHK1 pathway to enhance CD81 T cell responses in lung squamous cell carcinomaANNALS OF ONCOLOGY, 2016, 27Huang, S-M.Wu, S-P.Liao, R-Q.Dong, Z-Y.Tu, H.Xie, Z.Su, J.Yang, J-J.Zhang, X.Wu, Y-L.
- [26] PD-1 blockade restores impaired function of ex vivo expanded CD8+T cells and enhances apoptosis in mismatch repair deficient EpCACAM+PD-L1+cancer cellsONCOTARGETS AND THERAPY, 2017, 10 : 3453 - 3465Kumar, RajeevYu, FangZhen, Yuan-HuanLi, BoWang, JunYang, YuanGe, Hui-XinHu, Ping-ShengXiu, Jin
- [27] FUNCTIONAL T CELL RESTORATION INDUCED BY PD-1/PD-L1 BLOCKADE IN CHRONIC HEPATITIS B AND C IS IMPROVED BY SIMULTANEOUS MODULATION OF THE CO-STIMULATORY CD137/CD137L PATHWAYJOURNAL OF HEPATOLOGY, 2009, 50 : S49 - S49Fisicaro, P.Urbani, S.Valdatta, C.Amadei, B.Andreone, P.Loggi, E.Bernardi, M.Villa, E.Missale, G.Ferrari, C.
- [28] Cyclin dependent kinase 9 (CDK9) inhibition increased efficacy of programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma (HCC) through decreasing programmed death-ligand 1 (PD-L1) expressionCANCER RESEARCH, 2023, 83 (07)Chen, Ching-TsoShao, Yu-YunHsu, Hung-WeiWo, Rita R.Wang, Han-YuCheng, Ann-LiiHsu, Chih-Hung
- [29] TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation (vol 5, pg 1834, 2024)NATURE CANCER, 2025, 6 (02) : 405 - 405Nutsch, KatherineBanta, Karl L.Wu, Thomas D.Tran, Charles W.Mittman, StephanieDuong, EllenNabet, Barzin Y.Qu, YanWilliams, KatherineMuller, SorenPatil, Namrata S.Chiang, Eugene Y.Mellman, Ira
- [30] Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinomaCARCINOGENESIS, 2020, 41 (07) : 894 - 903Wu, YunyanSang, MeixiangLiu, FeiZhang, JiandongLi, WeijingLi, ZhenhuaGu, LinaZheng, YangLi, JuanShan, Baoen